ImmuPharmaLSE:IMM +7.77% Return-on-Tangible-Equity is 12.17% as of Dec. 2025. The stock has 3 warning signs investors should review. Among 1,195 Biotechnology companies, ImmuPharma ranks worse than 97.66% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. ImmuPharma's annualized net income for the quarter that ended in Dec. 2025 was £0.06 Mil. ImmuPharma's average shareholder tangible equity for the quarter that ended in Dec. 2025 was £0.51 Mil. Therefore, ImmuPharma's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was 12.17%.
The historical rank and industry rank for ImmuPharma's Return-on-Tangible-Equity or its related term are showing as below:
LSE:IMM'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -9029.09 Med: -147.01 Max: -98.27
Current: -1163.95
During the past 13 years, ImmuPharma's highest Return-on-Tangible-Equity was -98.27%. The lowest was -9,029.09%. And the median was -147.01%.
LSE:IMM's Return-on-Tangible-Equity is ranked worse than 97.66% of 1195
companies
in the Biotechnology industry
Industry Median: -42.21
vs LSE:IMM: -1163.95
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
ImmuPharma Return-on-Tangible-Equity Related Terms
ImmuPharma Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for ImmuPharma's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:IMM vs VRTX, REGN, ALNY: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, ImmuPharma's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ImmuPharma Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ImmuPharma's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where ImmuPharma's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 12.17% mean?
ImmuPharma (LSE:IMM) has a Return-on-Tangible-Equity of 12.17% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on ImmuPharma and its competitors. According to the industry distribution chart, ImmuPharma ranks #1167 out of 1195 companies in the Biotechnology industry, placing it in the top 97.7%.
Is ImmuPharma's Return-on-Tangible-Equity too high?
ImmuPharma's current Return-on-Tangible-Equity is 12.17%. Based on the distribution chart, ImmuPharma ranks #1167 out of 1195 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does ImmuPharma's Return-on-Tangible-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, ImmuPharma ranks #1167 out of 1195 companies for Return-on-Tangible-Equity. This places ImmuPharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on ImmuPharma and its competitors. ImmuPharma's current Return-on-Tangible-Equity is 12.17%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ImmuPharma stock overvalued right now?
ImmuPharma (LSE:IMM) has a current Return-on-Tangible-Equity of 12.17%. The current Return-on-Tangible-Equity is 12.17%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For ImmuPharma (LSE:IMM), the current Return-on-Tangible-Equity is 12.17% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ImmuPharma PLC focuses on the research, development, and commercialisation of pioneering and novel drugs in specialist therapeutic areas within the pharmaceutical industry. The company's pipeline products are P140, CDx, Kapiglucagon, BioAMB, and BioCIN.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:IMM has been successfully added to your 